Bio-Rad Laboratories BIO Clinical Diagnostics — Goodwill, Impaired, Accumulated Impairment Loss

Other segment segments

Similar metrics at other companies

RKTDirect to Consumer — Goodwill, Impaired, Accumulated Impairment Loss

$0—

SPXCCost of products sold — Goodwill, Impaired, Accumulated Impairment Loss

$175.5M+0.9%

OSKCorporate And Other — Goodwill Impaired Accumulated Impairment Loss

$44.4M+14.7%

ROKLifecycle Services — Goodwill, Impaired, Accumulated Impairment Loss

$319M+102%

MYRGC&I — Goodwill, Impaired, Accumulated Impairment Loss

$0—

SPXCDetection and Measurement reportable segment — Goodwill, Impaired, Accumulated Impairment Loss

$175.8M+1.7%

Questions, answered.

What is Bio-Rad Laboratories's clinical diagnostics — goodwill, impaired, accumulated impairment loss?

Bio-Rad Laboratories (BIO) reported clinical diagnostics — goodwill, impaired, accumulated impairment loss of $293.4M in Q1 2026.

How has Bio-Rad Laboratories's clinical diagnostics — goodwill, impaired, accumulated impairment loss changed year-over-year?

Bio-Rad Laboratories's clinical diagnostics — goodwill, impaired, accumulated impairment loss decreased by 0.0% year-over-year, from $293.4M to $293.4M.

What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — goodwill, impaired, accumulated impairment loss?

Over 4 years (2021 to 2025), Bio-Rad Laboratories's clinical diagnostics — goodwill, impaired, accumulated impairment loss has grown at a 0.0% compound annual growth rate (CAGR), from $1.17B to $1.17B.

What does clinical diagnostics — goodwill, impaired, accumulated impairment loss mean?

The cumulative total of impairment charges recognized against goodwill within the Clinical Diagnostics segment. It reflects the historical reduction in the carrying value of goodwill due to declines in the fair value of the reporting unit.